RESUMO
In this review, authors considered characteristics of depression and alcohol addiction. Depressive disorders comorbid to alcoholism are heterogeneous in their nature and structure and can be observed during alcohol withdrawal syndrome and in remission. Antidepressants, and first of all selective serotonin reuptake inhibitors (SSRIs), along with the specific anti-relapse drugs (disulfiram, acamprosate and naltrexone), are the drugs of choice in treatment of alcohol addiction. Efficient combinations of pharmacotherapy and psychotherapy can improve outcomes of both comorbid disorders.
Assuntos
Alcoolismo/diagnóstico , Alcoolismo/epidemiologia , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/epidemiologia , Acamprosato , Dissuasores de Álcool/uso terapêutico , Alcoolismo/terapia , Antidepressivos/uso terapêutico , Comorbidade , Transtorno Depressivo/terapia , Dissulfiram/uso terapêutico , Humanos , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Psicoterapia , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Síndrome de Abstinência a Substâncias/epidemiologia , Taurina/análogos & derivados , Taurina/uso terapêuticoRESUMO
The efficiency of potentiated preparations from ethanol and morphine hydrochloride in the therapy of patients with alcohol and opium withdrawal syndromes was compared in an open clinical trial. Potentiated ethanol relieved the major clinical manifestations, possessed hypnagogic properties, and reduced the severity of neurological and vegetative disorders in patients with the alcohol withdrawal syndrome. Potentiated morphine produced the anxiolytic, myorelaxing, and analgetic effects. Test preparations did not cause side effects.
Assuntos
Etanol/uso terapêutico , Morfina/uso terapêutico , Psicotrópicos/uso terapêutico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Homeopatia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
The efficiency of Proproten-100 containing antibodies to S100 protein in ultralow doses and used to relieve somatovegetative and psychoneurological manifestations of the alcohol withdrawal syndrome was studied in a double-blind, placebo-controlled clinical trial. The preparation possessed anxiolytic, sedative, hypnagogic, and vegetostabilizing properties. Proproten-100 more rapidly relieved the alcohol withdrawal syndrome than standard drugs (by 2 times). Proproten-100 may used in combination with detoxicating and symptomatic drugs to treat patients with severe disorders. The preparation did not cause side effects. Our observations indicate that Proproten-100 may be used alone (monotherapy) or in combination with standard pharmaceutics for treatment of patients with the alcohol withdrawal syndrome.
Assuntos
Alcoolismo/tratamento farmacológico , Anticorpos/imunologia , Anticorpos/uso terapêutico , Proteínas S100/imunologia , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Adulto , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
We studied the efficiency of ANAR containing antibodies to morphine (dilutions C300 and C200) in the therapy of patients with the opium withdrawal syndrome. In patients with moderate to severe forms of the opium withdrawal syndrome therapeutic activity of ANAR was comparable to that of standard symptomatic drugs. ANAR possessed vegetostabilizing, sedative, and analgetic properties. Treatment with ANAR allowed us to reduce doses of psychotropic and analgetic preparations and delay the development of withdrawal symptoms by 18-24 h.